Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 12/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22032112 | 0.85 | TP53 (0.35) | TP53TDP1CHRM1HSD11B1CHRM2 | |
| SCHEMBL31694629 | 0.84 | KCNH2 (0.35) | TP53TDP1 | |
| SCHEMBL31694637 | 0.84 | KCNH2 (0.35) | TP53TDP1 | |
| SCHEMBL20585810 | 0.84 | KCNH2 (0.35) | TP53TDP1 | |
| SCHEMBL20585811 | 0.84 | KCNH2 (0.35) | TP53TDP1 | |
| SCHEMBL20585812 | 0.84 | KCNH2 (0.35) | TP53TDP1 | |
| SCHEMBL22032103 | 0.82 | TP53 (0.32) | TP53TDP1CHRM1 | |
| SCHEMBL22032105 | 0.81 | TP53 (0.39) | TP53TDP1CHRM1HSD11B1GAA | |
| SCHEMBL10639129 | 0.81 | GAA (0.35) | TP53TDP1CHRM1HSD11B1GAA | |
| SCHEMBL24106280 | 0.80 | CHRM1 (0.40) | TP53TDP1CHRM1HSD11B1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11945801-B2 | Bicyclic aza compounds as muscarinic M1 and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2024-04-02 | — | — | US | disclosed |
| US-20210387969-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2021-12-16 | — | — | US | disclosed |
| US-20210387969-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2021-12-16 | — | — | US | disclosed |
| EP-3891140-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS | Heptares Therapeutics Limited (GB) | 2021-10-13 | — | — | EP | disclosed |
| WO-2020115505-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-06-11 | — | — | WO | disclosed |
| WO-2020115505-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210387969-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM4 | TP53 1761/4885TDP1 1802/4885CHRM1 1/4885 |
| US-11945801-B2 | Bicyclic aza compounds as muscarinic M1 and/or M4 receptor agonists | CHRM1, CHRM2, CHRM4 | TP53 1761/4885TDP1 1802/4885CHRM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.